JP2020516639A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516639A5 JP2020516639A5 JP2019555784A JP2019555784A JP2020516639A5 JP 2020516639 A5 JP2020516639 A5 JP 2020516639A5 JP 2019555784 A JP2019555784 A JP 2019555784A JP 2019555784 A JP2019555784 A JP 2019555784A JP 2020516639 A5 JP2020516639 A5 JP 2020516639A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- alkyl
- halo
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C1-4 alkyl hydrogen Chemical compound 0.000 claims 121
- 150000001875 compounds Chemical class 0.000 claims 52
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 29
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 25
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 21
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000003107 substituted aryl group Chemical group 0.000 claims 13
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 201000001981 dermatomyositis Diseases 0.000 claims 8
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims 8
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000005955 1H-indazolyl group Chemical group 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- 239000006143 cell culture medium Substances 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 206010061598 Immunodeficiency Diseases 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000007813 immunodeficiency Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical class 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical class 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 206010061979 Genital pain Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 claims 1
- 241000590503 Melanitis Species 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 208000010346 Sphingolipidoses Diseases 0.000 claims 1
- 201000001307 Sphingolipidosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 239000007640 basal medium Substances 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 235000008001 rakum palm Nutrition 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484692P | 2017-04-12 | 2017-04-12 | |
| US62/484,692 | 2017-04-12 | ||
| US201862613382P | 2018-01-03 | 2018-01-03 | |
| US62/613,382 | 2018-01-03 | ||
| US201862625896P | 2018-02-02 | 2018-02-02 | |
| US62/625,896 | 2018-02-02 | ||
| PCT/US2018/027265 WO2018191476A1 (en) | 2017-04-12 | 2018-04-12 | Aryl hydrocarbon receptor antagonists and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516639A JP2020516639A (ja) | 2020-06-11 |
| JP2020516639A5 true JP2020516639A5 (https=) | 2021-05-27 |
| JP7352807B2 JP7352807B2 (ja) | 2023-09-29 |
Family
ID=62090081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555784A Active JP7352807B2 (ja) | 2017-04-12 | 2018-04-12 | アリール炭化水素受容体アンタゴニスト及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10457683B2 (https=) |
| EP (1) | EP3609890B1 (https=) |
| JP (1) | JP7352807B2 (https=) |
| KR (1) | KR20190138837A (https=) |
| CN (1) | CN110785419B (https=) |
| AU (1) | AU2018253115B2 (https=) |
| BR (1) | BR112019021282A2 (https=) |
| CA (1) | CA3057159A1 (https=) |
| CO (1) | CO2019012473A2 (https=) |
| IL (2) | IL293956A (https=) |
| MX (1) | MX392743B (https=) |
| SG (1) | SG11201908624SA (https=) |
| TW (1) | TW201841916A (https=) |
| WO (1) | WO2018191476A1 (https=) |
| ZA (1) | ZA201906209B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| BR112020003116A2 (pt) | 2017-08-17 | 2020-08-04 | Ikena Oncology, Inc. | inibidores de ahr e usos dos mesmos |
| US20190314407A1 (en) * | 2017-10-31 | 2019-10-17 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| US20200338132A1 (en) * | 2018-01-03 | 2020-10-29 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| CN113301897A (zh) * | 2018-10-17 | 2021-08-24 | 美真达治疗公司 | 用芳烃受体拮抗剂治疗癌症的方法 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| WO2021028382A1 (en) * | 2019-08-12 | 2021-02-18 | Bayer Aktiengesellschaft | [1,2,4]triazolo[1,5-c]quinazolin-5-amines |
| EP4051298A1 (en) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CA3201841A1 (en) | 2020-12-23 | 2022-06-30 | Scott Bryan HOYT | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
| WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
| WO2023250431A2 (en) * | 2022-06-22 | 2023-12-28 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5233044A (en) | 1989-06-08 | 1993-08-03 | Millipore Corporation | Active esters for solid phase peptide synthesis |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US6447766B1 (en) | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| ES2210255T3 (es) | 1993-06-08 | 2004-07-01 | Smithkline Beecham Corporation | Metodos para mejorar la actividad biologica de quimiocinas. |
| US5547892A (en) | 1995-04-27 | 1996-08-20 | Taiwan Semiconductor Manufacturing Company | Process for forming stacked contacts and metal contacts on static random access memory having thin film transistors |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| KR100463630B1 (ko) | 1997-02-11 | 2005-05-25 | 말린크로트, 인코포레이티드 | 고상 펩티드 합성용 반응기 및 방법_ |
| ES2156581T5 (es) | 1998-03-30 | 2015-01-21 | Northwest Biotherapeutics, Inc. | Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| DE10120829A1 (de) | 2000-04-27 | 2001-12-20 | Max Delbrueck Centrum | Sleeping Beauty, ein Transposonvektor mit breitem Wirtsbereich für die genetische Transformation bei Wirbeltieren |
| EP1286684B1 (en) | 2000-05-09 | 2004-04-28 | The University Of British Columbia | use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| MXPA02012067A (es) | 2000-06-05 | 2004-08-19 | Univ Columbia | Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico. |
| JP5170934B2 (ja) | 2001-08-16 | 2013-03-27 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用 |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| MY133311A (en) | 2002-09-19 | 2007-11-30 | Schering Corp | Novel imidazopyridines as cyclin dependent kinase inhibitors |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| US7622108B2 (en) | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
| JP2008509928A (ja) | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US20070033666A1 (en) | 2005-06-24 | 2007-02-08 | Harris Reuben S | Using cytosine deaminases to diminish retroelement transfer from pigs to humans |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| TW200803863A (en) | 2005-11-10 | 2008-01-16 | Schering Corp | Method for inhibiting protein kinases |
| CN101421393B (zh) | 2006-02-14 | 2013-08-14 | 塞勒兰特治疗公司 | 提高造血干细胞植入的方法和组合物 |
| WO2007145227A1 (ja) | 2006-06-14 | 2007-12-21 | Chugai Seiyaku Kabushiki Kaisha | 造血幹細胞増加促進剤 |
| US8372797B2 (en) | 2006-06-22 | 2013-02-12 | Creative Medical Health, Inc. | Treatment of erectile dysfunction by stem cell therapy |
| EP1995316A1 (de) | 2007-05-25 | 2008-11-26 | Qiagen GmbH | Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen |
| EP2009095A1 (en) | 2007-06-28 | 2008-12-31 | Innovalor AG | Method of generating glucose-responsive cells |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010085699A2 (en) | 2009-01-23 | 2010-07-29 | The Johns Hopkins University | Mammalian piggybac transposon and methods of use |
| EP2270025A1 (en) | 2009-06-29 | 2011-01-05 | Centre National pour la Recherche Scientifique (CNRS) | Solid phase peptide synthesis of peptide alcohols |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2533629B1 (en) | 2010-02-11 | 2018-11-28 | Recombinetics, Inc. | Methods and materials for producing transgenic artiodactyls |
| CN103459031A (zh) * | 2010-12-16 | 2013-12-18 | 能源技术公司 | 催化剂、催化剂的制备方法、脱氧的方法以及用于燃料制造的系统 |
| JP2013545776A (ja) | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821819A1 (en) * | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| MX363013B (es) | 2011-02-25 | 2019-03-04 | Recombinetics Inc | Animales genéticamente modificados y métodos para su obtención. |
| US8673905B2 (en) * | 2011-03-17 | 2014-03-18 | Hoffmann-La Roche Inc. | Imidazo pyrazines |
| WO2012136531A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridines and intermediates thereof |
| EP2788476B1 (en) * | 2011-12-08 | 2019-05-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| US9388212B2 (en) | 2013-02-21 | 2016-07-12 | Chemical & Biopharmaceutical Laboratories Of Patras S.A. | Solid phase peptide synthesis via side chain attachment |
| WO2014080241A1 (en) | 2012-11-21 | 2014-05-30 | Piramal Enterprises Limited | Imidazopyridine compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US9169287B2 (en) | 2013-03-15 | 2015-10-27 | Massachusetts Institute Of Technology | Solid phase peptide synthesis processes and associated systems |
| WO2015048570A2 (en) | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
| US10117899B2 (en) | 2013-10-17 | 2018-11-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| HK1256681A1 (zh) | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| HK1254892A1 (zh) * | 2016-01-14 | 2019-08-02 | 韩德株式会社 | 拮抗a3腺苷受体的化合物、其制备方法、及其医学用途 |
| EP4049665B1 (en) | 2016-03-15 | 2025-03-12 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) * | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| EP3703715A1 (en) | 2017-10-31 | 2020-09-09 | Magenta Therapeutics, Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| US20190314407A1 (en) | 2017-10-31 | 2019-10-17 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
-
2018
- 2018-04-12 TW TW107112606A patent/TW201841916A/zh unknown
- 2018-04-12 WO PCT/US2018/027265 patent/WO2018191476A1/en not_active Ceased
- 2018-04-12 JP JP2019555784A patent/JP7352807B2/ja active Active
- 2018-04-12 AU AU2018253115A patent/AU2018253115B2/en not_active Ceased
- 2018-04-12 IL IL293956A patent/IL293956A/en unknown
- 2018-04-12 MX MX2019011138A patent/MX392743B/es unknown
- 2018-04-12 BR BR112019021282A patent/BR112019021282A2/pt not_active IP Right Cessation
- 2018-04-12 CN CN201880040109.4A patent/CN110785419B/zh active Active
- 2018-04-12 SG SG11201908624S patent/SG11201908624SA/en unknown
- 2018-04-12 US US15/951,585 patent/US10457683B2/en active Active
- 2018-04-12 EP EP18721236.0A patent/EP3609890B1/en active Active
- 2018-04-12 KR KR1020197033072A patent/KR20190138837A/ko not_active Withdrawn
- 2018-04-12 CA CA3057159A patent/CA3057159A1/en active Pending
-
2019
- 2019-02-08 US US16/271,376 patent/US10351572B2/en active Active
- 2019-09-13 US US16/570,045 patent/US10919900B2/en active Active
- 2019-09-19 ZA ZA2019/06209A patent/ZA201906209B/en unknown
- 2019-09-23 IL IL26957419A patent/IL269574A/en unknown
- 2019-11-07 CO CONC2019/0012473A patent/CO2019012473A2/es unknown
-
2020
- 2020-12-18 US US17/126,524 patent/US20210179625A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516639A5 (https=) | ||
| CA2862140C (en) | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells | |
| US10351572B2 (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| Asai et al. | Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. | |
| AU2010333804B2 (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| WO2020051207A2 (en) | Aryl hydrocarbon receptor antagonists and methods of use | |
| US20230338429A1 (en) | Compounds and use thereof in the expansion of stem cells and/or progenitor cells | |
| US12011460B2 (en) | Expansion of NK and DC cells in vivo mediating immune response | |
| EP3704232A1 (en) | Compositions and methods for the expansion of hematopoietic stem and progenitor cells | |
| JP2021502824A5 (https=) | ||
| JP2021503008A5 (https=) | ||
| US20220273716A1 (en) | Populations of natural killer cells comprising a cd38 chimeric antigen receptor | |
| Bin et al. | Effects of ammonia nitrogen stress on activities of non-specific immune enzymes of sea cucumber Luhai No. 1. | |
| Peled et al. | Effect of M20 interleukin-1 inhibitor on normal and leukemic human myeloid progenitors | |
| WO2020092694A2 (en) | Methods for hematopoietic stem and progenitor cell transplant therapy | |
| EP3735412A1 (en) | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders | |
| Peled et al. | Effect of M20 interleukin-1 inhibitor on normal and leukemic human | |
| TW198721B (https=) | ||
| Conrad | Stephen G. Emerson, MD, Ph. D. and | |
| NZ733858B2 (en) | Compounds and methods for modulating tmprss6 expression |